# United Immunity, Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/united-immunity-co

- Industry: Healthcare Specialists
- Headquarters: Tokyo, Japan
- Website: www.unitedimmunity.co.jp
- Total disclosed funding: $11M
- Latest round: Series B (Sep 11, 2023)
- Investors on record: 6

## About

Founded in 2017  and based in Tokyo, Japan, United Immunity, Co., Ltd. specializes in innovative drug delivery systems, merging immunotherapy with nanoparticle technology to enhance therapeutic efficacy in treating various diseases, including cancer and autoimmune disorders. United Immunity, Co., Ltd. focuses on developing advanced drug delivery systems. Naozumi Harada is the founder, with a history of involvement in the biotechnology sector. United Immunity Co., Ltd. specializes in the development of innovative drug delivery systems that integrate immunotherapy and nanoparticle technology. Core products like Pullulan Nanoparticles (PNP) and Pullulan-Lipid Nanoparticles (P-LNP) are engineered to selectively deliver therapeutic agents to myeloid cells to enhance treatments for diseases such as cancer and autoimmune disorders. The company targets pharmaceutical and research institutions across North America, Europe, and Asia.The revenue model of United Immunity is based on partnerships with pharmaceutical and biotech companies to develop and commercialize proprietary drug delivery systems. Through B2B transactions, the company generates revenue via licensing agreements and collaborations, involving milestone payments and royalties based on the success of the drugs delivered using their Myeloid Targeting Platform™. In September 2026, United Immunity, Co., Ltd. raised JPY 1.8 billion in venture funding from Itochu, Ono Venture Investment, Mizuho Capital, Miyako Capital, Fujita Innovation Capital, Nippon Venture Capital and Kobe University Capital, Venture Labo Investment, Saisei Ventures, University of Tokyo Edge Capital Partners and Mitsubishi UFJ Capital. and venture debt funding   Joyo Bank and Aozora Corporate Investment. This round was part of a larger JPY 2.2 billion equity and venture debt funding. It also received? JPY 2.8 billion?in?grant ?funding ?from new Japan Agency for Medical Research and Development.
The company plans to use the September 2026 funds to accelerate the clinical development of UI-102 and its in vivo immunotherapy programs.

## Funding rounds

- Series B, Sep 11, 2023, $5.6M — University of Tokyo Edge Capital Partners, Venture Labo Investment, Saisei Ventures, Toho Holdings
- Series B, Sep 7, 2021, $4.5M — University of Tokyo Edge Capital Partners, KISCO
- Series A, Dec 9, 2020, $0.8M — Axil Capital

## Investors

- Axil Capital (https://capitalatlas.ai/funds/axil-capital) — Series A
- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Series B
- KISCO — Series B
- Venture Labo Investment (https://capitalatlas.ai/funds/venture-labo-investment) — Series B
- Saisei Ventures (https://capitalatlas.ai/funds/saisei-ventures) — Series B
- Toho Holdings — Series B